Literature DB >> 31188018

Dosimetric performance of two linear accelerator-based radiosurgery systems to treat single and multiplebrain metastases.

Yoshihiro Ueda1, Shingo Ohira1, Hideya Yamazaki2, Nobuhisa Mabuchi2, Naokazu Higashinaka2, Masayoshi Miyazaki1, Teruki Teshima1.   

Abstract

OBJECTIVE: To evaluate and compare the dosimetric plan quality for noncoplanar volumetric arc therapy of single and multiple brain metastases using the linear accelerator-based radiosurgery system HyperArc and a robotic radiosurgery system.
METHODS: 31 tumors from 24 patients were treated by stereotactic radiosurgery using the CyberKnife system. CT images, structure sets, and dose files were transferred to the Eclipse treatment planning system for the HyperArc system. Dosimetric parameters for both plans were compared. The beam-on time was calculated from the total monitor unit and dose rate.
RESULTS: For normal brain tissue, the received volume doses were significantly lower for HyperArc than for CyberKnife_G4 and strongly correlated with the planning target volume (PTV) for cases of single brain metastasis. In addition, the difference in volume dose between CyberKnife_G4 and HyperArc was proportional to the PTV. For multiple brain metastases, no significant difference was observed between the two stereotactic radiosurgery systems, except for high-dose region in the normal tissue. In low dose for brain minus PTV, when the maximum distance among each target was above 8.0 cm, HyperArc delivered higher dose than CyberKnife_G4. The mean ± SDs for the beam-on time were 15.8 ± 5.3 and 5.6 ± 0.8 min for CyberKnife_G4 and HyperArc, respectively (p < .01).
CONCLUSION: HyperArc is best suited for larger targets in single brain metastasis and for smaller inter tumor tumor distances in multiple brain metastases. ADVANCES IN KNOWLEDGE: The performance of HyperArc in comparison with CyberKnife_G4 was depended on defined margin and tumor distances.

Entities:  

Mesh:

Year:  2019        PMID: 31188018      PMCID: PMC6724620          DOI: 10.1259/bjr.20190004

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  23 in total

1.  Patterns of patient movement during frameless image-guided radiosurgery.

Authors:  Martin J Murphy; Steven D Chang; Iris C Gibbs; Quynh-Thu Le; Jenny Hai; Daniel Kim; David P Martin; John R Adler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

Review 2.  The CyberKnife stereotactic radiosurgery system: description, installation, and an initial evaluation of use and functionality.

Authors:  John S Kuo; Cheng Yu; Zbigniew Petrovich; Michael L J Apuzzo
Journal:  Neurosurgery       Date:  2003-11       Impact factor: 4.654

3.  Intrafraction geometric uncertainties in frameless image-guided radiosurgery.

Authors:  Martin J Murphy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-10       Impact factor: 7.038

4.  An overview of hypofractionation and introduction to this issue of seminars in radiation oncology.

Authors:  Robert D Timmerman
Journal:  Semin Radiat Oncol       Date:  2008-10       Impact factor: 5.934

5.  Reirradiation of brain metastases with radiosurgery.

Authors:  Ernesto Maranzano; Fabio Trippa; Michelina Casale; Sara Costantini; Paola Anselmo; Sandro Carletti; Massimo Principi; Claudia Caserta; Fabio Loreti; Cesare Giorgi
Journal:  Radiother Oncol       Date:  2011-08-29       Impact factor: 6.280

6.  Time dependence of intrafraction patient motion assessed by repeat stereoscopic imaging.

Authors:  Mischa S Hoogeman; Joost J Nuyttens; Peter C Levendag; Ben J M Heijmen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-08       Impact factor: 7.038

7.  Dosimetric comparison of different treatment modalities for stereotactic radiosurgery of arteriovenous malformations and acoustic neuromas.

Authors:  Thierry Gevaert; Marc Levivier; Thomas Lacornerie; Dirk Verellen; Benedikt Engels; Nick Reynaert; Koen Tournel; Michael Duchateau; Truus Reynders; Tom Depuydt; Christine Collen; Eric Lartigau; Mark De Ridder
Journal:  Radiother Oncol       Date:  2012-08-10       Impact factor: 6.280

8.  Radiation therapy for brain metastases.

Authors:  J G Cairncross; J H Kim; J B Posner
Journal:  Ann Neurol       Date:  1980-06       Impact factor: 10.422

9.  Dosimetric superiority of flattening filter free beams for single-fraction stereotactic radiosurgery in single brain metastasis.

Authors:  Youqun Lai; Shanyu Chen; Changdong Xu; Liwan Shi; Lirong Fu; Huiming Ha; Qin Lin; Zhen Zhang
Journal:  Oncotarget       Date:  2017-05-23

10.  In silico assessment of the dosimetric quality of a novel, automated radiation treatment planning strategy for linac-based radiosurgery of multiple brain metastases and a comparison with robotic methods.

Authors:  Krzysztof Slosarek; Barbara Bekman; Jacek Wendykier; Aleksandra Grządziel; Antonella Fogliata; Luca Cozzi
Journal:  Radiat Oncol       Date:  2018-03-15       Impact factor: 3.481

View more
  4 in total

1.  Clinical implementation of HyperArc.

Authors:  Felix H C Wong; Puleng A Moleme; Omer A Ali; Koki V Mugabe
Journal:  Phys Eng Sci Med       Date:  2022-04-11

2.  Dosimetric comparison between RapidArc and HyperArc techniques in salvage stereotactic body radiation therapy for recurrent nasopharyngeal carcinoma.

Authors:  Hsiu-Wen Ho; Steve P Lee; Hisu-Man Lin; Hsiao-Yun Chen; Chun-Chiao Huang; Shih-Chang Wang; Ching-Chieh Yang; Yu-Wei Lin
Journal:  Radiat Oncol       Date:  2020-07-08       Impact factor: 3.481

3.  Novel strategy with the automatic non-coplanar volumetric-modulated arc therapy for angiosarcoma of the scalp.

Authors:  Shoki Inui; Yoshihiro Ueda; Shingo Ohira; Haruhi Tsuru; Masaru Isono; Masayoshi Miyazaki; Masahiko Koizumi; Teruki Teshima
Journal:  Radiat Oncol       Date:  2020-07-17       Impact factor: 3.481

4.  The new SRS/FSRT technique HyperArc for benign brain lesions: a dosimetric analysis.

Authors:  Hsiu-Wen Ho; Ching-Chieh Yang; Hsiu-Man Lin; Hsiao-Yun Chen; Chun-Chiao Huang; Shih-Chang Wang; Yu-Wei Lin
Journal:  Sci Rep       Date:  2021-10-26       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.